Telix Pharmaceuticals Ltd
TLXHealthcare|Biotechnology|Australia
$11.14
-0.65 (-5.47%)
Financials
Financial Snapshot
Market Cap
$3.80B
Enterprise Value
$-340.5M
Revenue (TTM)
$803.8M
Net Income (TTM)
$-7.1M
Cash & Equivalents
—
Net Cash/Share
$-1.85
Free Cash Flow (TTM)
$-61.1M
Operating CF (TTM)
$-17.3M
Debt/Equity
1.13
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$4.3M
Monthly Burn
$1.4M
Est. Runway
—
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.6M | $40.3M | $18.2M | $31.2M | $59.9M | $16.0M | $79.1M | $84.3M | $440.0M | $141.9M | $141.9M | |
| Operating Cash Flow | $0.00 | $0.00 | $-14.6M | $-16.3M | $1.5M | $-43.0M | $-43.5M | $14.3M | $27.5M | $-17.3M | $-17.3M | |
| Free Cash Flow | $0.00 | $0.00 | $-14.6M | $-16.7M | $1.3M | $-44.0M | $-52.9M | $7.2M | $5.3M | $-61.1M | $-61.1M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $-328.0K | $-248.0K | $-971.0K | $-9.4M | $-7.1M | $-22.2M | $-43.8M | $-43.8M | |
| Financing Cash Flow | $0.00 | $0.00 | $-612.0K | $29.9M | $26.2M | $2.1M | $119.0M | $7.1M | $416.8M | $-3.7M | $-3.7M |
R&D Spending
R&D (TTM)
$171.2M
R&D Intensity
21.3%
R&D Growth YoY
+0.0%
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $137.0K | $2.4M | $3.6M | $3.6M | $108.9M | $333.0M | $516.6M | $803.8M | $803.8M | |
| R&D Expense | $0.00 | $0.00 | $13.2M | $14.8M | $17.7M | $24.7M | $54.9M | $85.3M | $127.9M | $171.2M | $171.2M | |
| R&D % of Revenue | — | — | 9610.9% | 607.2% | 493.3% | 696.8% | 50.4% | 25.6% | 24.8% | 21.3% | 21.3% | |
| SG&A | $186.0K | $0.00 | $6.4M | $8.1M | $14.8M | $29.6M | $59.5M | $89.4M | $152.2M | $237.1M | $237.1M |
Income Statement
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $137.0K | $2.4M | $3.6M | $3.6M | $108.9M | $333.0M | $516.6M | $803.8M | $803.8M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $1.8M | $1.6M | $1.8M | $44.3M | $123.4M | $180.4M | $377.4M | $377.4M | |
| Gross Profit | $0.00 | $0.00 | $137.0K | $659.0K | $2.0M | $1.7M | $64.6M | $209.5M | $336.2M | $426.4M | $426.4M | |
| R&D | $0.00 | $0.00 | $13.2M | $14.8M | $17.7M | $24.7M | $54.9M | $85.3M | $127.9M | $171.2M | $171.2M | |
| SG&A | $186.0K | $0.00 | $6.4M | $8.1M | $14.8M | $29.6M | $59.5M | $89.4M | $152.2M | $237.1M | $237.1M | |
| Operating Income | $-273.0K | $0.00 | $-19.5M | $-28.2M | $-38.3M | $-71.6M | $-50.5M | $35.0M | $55.6M | $18.1M | $18.1M | |
| Interest Expense | $0.00 | $0.00 | $-20.0K | $-1.7M | $-903.0K | $-3.8M | $-4.5M | $-8.9M | $-24.1M | $-40.4M | $-40.4M | |
| Pretax Income | $-270.0K | $0.00 | $-11.1M | $-21.8M | $-36.9M | $-58.3M | $-67.1M | $2.6M | $37.9M | $-5.3M | $-5.3M | |
| Net Income | $-270.0K | $0.00 | $-9.7M | $-19.5M | $-34.5M | $-58.4M | $-70.8M | $4.2M | $33.7M | $-7.1M | $-7.1M | |
| EPS (Diluted) | -0.01 | 0.00 | -0.05 | -0.08 | -0.13 | -0.21 | -0.23 | 0.01 | 0.10 | -0.02 | -0.02 | |
| EBITDA | $-273.0K | $0.00 | $-11.0M | $-17.1M | $-32.2M | $-50.8M | $-62.6M | $11.5M | $62.1M | $35.1M | $35.1M | |
| Shares Out. (M) | 38.66 | 38.66 | 202.12 | 233.44 | 257.27 | 282.21 | 310.64 | 337.88 | 345.19 | 323.71 | 310.36 |
Balance Sheet
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $40.3M | $18.2M | $31.2M | $59.9M | $16.0M | $79.1M | $84.3M | $440.0M | $141.9M | $141.9M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $1.7M | $41.0M | $25.3M | $41.1M | $72.0M | $34.5M | $117.8M | $158.7M | $570.1M | $330.3M | $330.3M | |
| Total Assets | $5.1M | $41.0M | $54.0M | $71.8M | $121.3M | $79.6M | $173.7M | $277.3M | $940.4M | $1.16B | $1.16B | |
| Total Current Liabilities | $191.0K | $615.0K | $5.8M | $7.4M | $15.3M | $27.5M | $58.2M | $111.4M | $205.1M | $231.6M | $231.6M | |
| Long-Term Debt | $0.00 | $0.00 | $420.0K | $204.0K | $73.0K | $0.00 | $2.3M | $5.9M | $341.8M | $391.9M | $391.9M | |
| Total Liabilities | $191.0K | $615.0K | $16.8M | $22.8M | $60.6M | $78.0M | $119.3M | $174.6M | $587.4M | $748.6M | $748.6M | |
| Stockholders' Equity | $4.9M | $40.4M | $37.3M | $49.1M | $60.8M | $1.6M | $54.4M | $102.6M | $352.9M | $415.4M | $415.4M | |
| Retained Earnings | $-3.3M | $-2.1M | $-14.2M | $-33.7M | $-71.5M | $-125.8M | $-185.6M | $-187.1M | $-152.9M | $-154.5M | $-154.5M |
Cash Flow Statement
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $0.00 | $-14.6M | $-16.3M | $1.5M | $-43.0M | $-43.5M | $14.3M | $27.5M | $-17.3M | $-17.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $-328.0K | $-248.0K | $-971.0K | $-9.4M | $-7.1M | $-22.2M | $-43.8M | $-43.8M | |
| Free Cash Flow | $0.00 | $0.00 | $-14.6M | $-16.7M | $1.3M | $-44.0M | $-52.9M | $7.2M | $5.3M | $-61.1M | $-61.1M | |
| Investing Cash Flow | $0.00 | $0.00 | $-1.9M | $-328.0K | $-839.0K | $-2.0M | $-11.6M | $-16.8M | $-86.7M | $-285.9M | $-285.9M | |
| Financing Cash Flow | $0.00 | $0.00 | $-612.0K | $29.9M | $26.2M | $2.1M | $119.0M | $7.1M | $416.8M | $-3.7M | $-3.7M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $31.7M | $27.0M | $2.7M | $123.2M | $4.2M | $662.0K | $1.8M | $1.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.1M | $4.2M | $427.9M | $529.0K | $529.0K | |
| Payments of Debt | $0.00 | $0.00 | $-612.0K | $-817.0K | $-695.0K | $-679.0K | $-869.0K | $-1.3M | $-2.1M | $-6.1M | $-6.1M | |
| Net Change in Cash | $0.00 | $0.00 | $-16.2M | $13.2M | $25.6M | $-40.5M | $64.1M | $5.5M | $355.7M | $-298.1M | $-298.1M |
Dilution Tracker
Shares Outstanding
310M
5-Year Share Growth
+10.0%
Stock Issuance (TTM)
$1.8M
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 38.66 | 38.66 | 202.12 | 233.44 | 257.27 | 282.21 | 310.64 | 337.88 | 345.19 | 323.71 | 310.36 | |
| YoY Change % | — | 0.0% | 422.8% | 15.5% | 10.2% | 9.7% | 10.1% | 8.8% | 2.2% | -6.2% | -4.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $31.7M | $27.0M | $2.7M | $123.2M | $4.2M | $662.0K | $1.8M | $1.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 27.0% | 56.8% | 48.0% | 59.3% | 62.9% | 65.1% | 53.1% | 53.0% | |
| Operating Margin % | 0.0% | 0.0% | -14215.3% | -1155.0% | -1063.9% | -2016.9% | -46.3% | 10.5% | 10.8% | 2.2% | 2.3% | |
| Net Margin % | 0.0% | 0.0% | -7110.9% | -799.5% | -959.2% | -1643.6% | -65.0% | 1.3% | 6.5% | -0.9% | -0.9% | |
| EBITDA Margin % | 0.0% | 0.0% | -8064.2% | -702.3% | -894.9% | -1430.5% | -57.5% | 3.5% | 12.0% | 4.4% | 4.4% | |
| FCF Margin % | 0.0% | 0.0% | -10668.6% | -682.9% | 35.0% | -1238.5% | -48.6% | 2.2% | 1.0% | -7.6% | -7.6% | |
| ROE % | -5.5% | 0.0% | -25.1% | -45.2% | -62.9% | -187.3% | -252.9% | 5.4% | 14.8% | -1.9% | -1.8% | |
| ROA % | -5.3% | 0.0% | -20.5% | -31.0% | -35.7% | -58.1% | -55.9% | 1.9% | 5.5% | -0.7% | -0.7% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 349.11 / 1313.16
Industry Med.27.41
P/S4.30
Historical2.34 / 86.67 / 1850.00
Industry Med.9.51
P/B8.82
Historical2.72 / 16.36 / 1083.75
Industry Med.2.93
EV/EBITDA112.28
Historical-46.15 / -14.79 / 482.86
Industry Med.13.14
EV/Revenue4.90
Historical2.75 / 73.47 / 1834.06
Industry Med.8.71
P/FCF—
Historical298.44 / 706.98 / 1328.33
Industry Med.27.54
Intrinsic Value Models
| Metric | Trend | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 530.53 | 159.81 | At Loss | At Loss | |
| PS Ratio | - | - | 0.00 | 103.33 | 198.95 | 430.56 | 13.98 | 6.85 | 10.41 | 3.00 | 4.30 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.61 | 6.11 | 8.82 | |
| EV/EBITDA | 0.00 | 0.00 | -7.68 | -14.04 | -22.98 | -30.83 | -23.64 | 183.08 | 82.77 | 80.98 | 112.28 | |
| EV/Revenue | 0.00 | 0.00 | 619.44 | 98.62 | 205.65 | 441.09 | 13.59 | 6.34 | 9.95 | 3.54 | 4.90 |
Analyst Estimates & Quality
Altman Z-Score
3.64
Safe
Piotroski F-Score
2
Weak
Beneish M-Score
-1.74
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $967.5M | $1,142.5M | $1,274.2M |
| Net Income | $14.0M | $45.8M | $104.1M |
| EPS | 0.05 | 0.15 | 0.34 |
| Book Value per Share | 1.21 | 1.56 | 1.55 |
| Operating Cash Flow per Share | 0.23 | 0.39 | 0.60 |
| Operating CF | $72.00M | $120.42M | $185.44M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Precision Medicine | $621.9M |
| Inter-segment elimianations | $-72.5M |
| Manufacturing Solutions | $245.1M |
| Therapeutics | $9.3M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $784.9M |
| China | $9.8M |
| Other countries | $9.1M |